Coya Therapeutics首席执行官Arun Swaminathan博士向股东发布信件投资者关系联系电子邮件提醒-动脉网

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders IR Contact Email Alerts

Coya Therapeutics 等信源发布 2026-01-20 21:50



可切换为仅中文







HOUSTON--(BUSINESS WIRE)--

休斯顿--（商业资讯）--

Coya Therapeutics, Inc.

科亚治疗公司

(NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan.

（纳斯达克股票代码：COYA）（“Coya”或“公司”），一家临床阶段的生物技术公司，致力于开发旨在增强Treg功能的生物制品，发布了以下来自首席执行官Arun Swaminathan博士致股东的信。

Dear Fellow Stockholders,

亲爱的股东们，

Coya enters 2026 with strong momentum and a clear sense of purpose. I believe we are exceptionally well positioned to advance our mission of delivering potentially transformational therapies for patients suffering from devastating neurodegenerative diseases. Scientifically, the neurodegeneration field increasingly recognizes combination-based therapeutic strategies such as ours as a promising path forward for diseases driven by complex, multifactorial biology.

Coya以强劲的势头和明确的目标进入了2026年。我相信我们已经为推进自己的使命——为那些遭受严重神经退行性疾病折磨的患者提供潜在变革性的疗法，做好了异常充分的准备。在科学上，神经退行性疾病领域越来越认识到像我们这样的基于组合的治疗策略，是应对由复杂、多因素生物学驱动疾病的前景广阔的道路。

Clinically, we are driving towards major clinical catalysts in ALS and FTD. We believe each program has the potential to meaningfully address unmet needs. Our studies are designed to evaluate whether combination-based regulatory T-cell modulation can stabilize or alter disease progression—an outcome that, if confirmed, would represent a significant advance for patients and a defining milestone for the Company.

在临床上，我们正朝着ALS（肌萎缩侧索硬化症）和FTD（额颞叶痴呆）领域的重要临床催化剂迈进。我们相信每个项目都有潜力有意义地满足未满足的需求。我们的研究旨在评估基于组合的调节性T细胞调节是否能够稳定或改变疾病进展——如果得到证实，这一结果将为患者带来重大突破，并成为公司的一个决定性里程碑。

Moreover, we anticipate additional datasets in 2026 which we believe are poised to add to our body of work on Treg biology..

此外，我们预计2026年会有更多数据集，我们认为这些数据集将为我们在Treg生物学方面的工作增添内容。

Operational and Regulatory Execution/Momentum

操作与监管执行/动力

Last year we received two important IND approvals for COYA 302—one in Amyotrophic Lateral Sclerosis (ALS) and one in Frontotemporal Dementia (FTD). We have now initiated our ALSTARS trial in ALS. That study is advancing as planned. We are actively enrolling and patients are already being dosed. Recruitment has been further strengthened by acceptance of our Clinical Trial Application (CTA) by Health Canada, enabling the activation of Canadian sites in addition to more than 20 U.S.

去年，我们获得了COYA 302的两项重要IND批准——一项针对肌萎缩侧索硬化症（ALS），另一项针对额颞叶痴呆（FTD）。我们现在已经启动了ALS中的ALSTARS试验。该研究正在按计划推进。我们正在积极招募患者，并且患者已经开始接受给药。加拿大卫生部对我们临床试验申请（CTA）的批准进一步增强了招募力度，使得除了美国的20多个试验点外，加拿大的试验点也得以启动。

clinical sites..

临床站点。。

Scientific Validation and Expanding Data Generation Built on Nobel Prize–Recognized Treg Biology

基于诺贝尔奖认可的Treg生物学的科学验证与数据生成扩展

Our scientific approach continues to be validated at the highest levels. In 2025, the Nobel Prize in Physiology or Medicine was awarded to our Scientific Advisory Board member, Dr. Shimon Sakaguchi, for his pioneering work in elucidating regulatory T-cell (Treg) biology.

我们的科学方法继续在最高水平上得到验证。2025年，诺贝尔生理学或医学奖授予了我们的科学顾问委员会成员坂口志文博士，以表彰他在阐明调节性T细胞（Treg）生物学方面的开创性工作。

Importantly, across four investigator-initiated clinical studies of our combination-based regulatory T-cell (Treg) modulation approach, we have observed stabilization of disease progression in treated patient cohorts, including ALS and FTD. Stabilizing clinical progression in neurodegenerative diseases, historically characterized by relentless functional decline, is a clinically meaningful signal and reinforces our belief in the potential of Treg-targeted combination strategies to alter disease trajectory.

重要的是，在我们基于组合的调节性T细胞（Treg）调节方法的四项研究者发起的临床研究中，我们观察到治疗患者群体的疾病进展趋于稳定，其中包括ALS（肌萎缩侧索硬化症）和FTD（额颞叶痴呆）。在神经退行性疾病中稳定临床进展，这些疾病历来表现为持续的功能衰退，这是一个具有临床意义的信号，进一步坚定了我们对Treg靶向组合策略改变疾病进程潜力的信心。

While investigator-initiated studies are not confirmatory, these results suggest a potentially unifying mechanism in neurodegeneration. In sum, we believe these observations provide early clinical validation of our approach and underpin our confidence in advancing COYA 302 in the ALSTARS Trial and a prospective clinical study in patients with FTD.

虽然研究者发起的研究并非确凿，但这些结果表明神经退行性疾病中可能存在一种潜在的统一机制。总之，我们认为这些观察结果为我们的方法提供了早期的临床验证，并增强了我们在ALSTARS试验中推进COYA 302以及在FTD患者中开展前瞻性临床研究的信心。

In addition, these observations also encourage our pursuit of later-stage development in other indications..

此外，这些观察结果也鼓励我们追求在其他适应症的后期开发。

New Translational Datasets to be provided in 2026

2026年将提供新的转化数据集

During 2026 we plan to present further translational and clinical datasets across our programs, including biomarker, proteomics, and single-cell data. These data are expected to further elucidate the role of regulatory T cells in modulating neuroinflammation and neurodegeneration, while providing deeper insight into target engagement, pathway modulation, and patient-level biology.

在2026年，我们计划展示更多跨项目的转化和临床数据集，包括生物标志物、蛋白质组学和单细胞数据。这些数据预计将进一步阐明调节性T细胞在调节神经炎症和神经退行性疾病中的作用，同时提供关于靶点参与、通路调节和患者水平生物学的更深入见解。

We believe these datasets will meaningfully strengthen the mechanistic foundation underlying our combination-based therapeutic approach and support future clinical, regulatory, and partnering discussions..

我们相信，这些数据集将有意义地加强我们基于组合的治疗方法的机制基础，并支持未来的临床、监管和合作伙伴讨论。

Financial Strength and Fiduciary Discipline

财务实力与信托纪律

In 2025, we further strengthened our balance sheet, including the receipt of $8.4 million in non-dilutive funding from our strategic partner, Dr. Reddy’s Laboratories. We enter 2026 with approximately $46.8 million in cash (unaudited) as of 31

在2025年，我们进一步巩固了资产负债表，包括从我们的战略合作伙伴Dr. Reddy's Laboratories获得了840万美元的非稀释性资金。截至31日，我们进入2026年的现金（未经审计）约为4680万美元。

开始

December 2025, no debt, and a projected cash runway into the second half of 2027—extending beyond the anticipated topline readout of the ALSTARS trial.

2025年12月，无债务，预计现金跑道将延续至2027年下半年——超出ALSTARS试验预期的头条数据读出时间。

This financial position allows us to remain highly focused on execution while preserving strategic flexibility.

这一财务状况使我们能够在保持战略灵活性的同时，高度专注于执行。

2026 Priorities and Clinical Programs

2026年重点和临床项目

Our efforts in 2026 will be squarely focused on advancing our ALS and FTD programs toward key value-creating milestones.

我们2026年的努力将完全集中于推动我们的ALS和FTD项目朝着创造关键价值的里程碑迈进。

COYA 302 in ALS

The ALSTARS Phase 2 trial is actively enrolling and dosing patients. Additional U.S. and Canadian sites are soon expected to come fully online. We are targeting full enrollment in the second half of 2026, with a topline data readout anticipated in the first quarter of 2027.

ALSTARS 第二阶段试验正在积极招募和给药患者。预计不久将有更多美国和加拿大的试验点全面上线。我们目标是在2026年下半年实现全面入组，并预计在2027年第一季度获得初步数据结果。

COYA 302 in FTD

FTD中的COYA 302

Results from an investigator-initiated trial of low-dose IL-2 and CTLA4-Ig demonstrated robust target engagement, including statistically significant and sustained increases in regulatory T-cell numbers and suppressive function beginning as early as two weeks post-dosing and maintained through the 22-week treatment period.

研究人员发起的低剂量IL-2和CTLA4-Ig试验结果表明，目标靶点得到了显著的结合，包括在给药后两周内即出现统计学上显著且持续的调节性T细胞数量增加及其抑制功能增强，并在22周的治疗期间一直维持。

The cognitive measures were stable, with no decline on either the Montreal Cognitive Assessment (MoCA) or the CDR-FTLD..

认知测量结果稳定，蒙特利尔认知评估（MoCA）和CDR-FTLD均未出现下降。

These results support advancement of COYA 302 into a Phase 2a study in patients with FTD, for which we have received FDA clearance. As previously disclosed, the Alzheimer’s Drug Discovery Foundation invested $5 million in Coya based on its conviction in our combination-therapy approach. We are working closely with leading key opinion leaders and expect to initiate this study in the second quarter of 2026.

这些结果支持将COYA 302推进到FTD患者的2a期研究，我们已经获得FDA的批准。正如之前披露的，阿尔茨海默病药物发现基金会基于对我们组合疗法的信心，向Coya投资了500万美元。我们正在与主要的意见领袖紧密合作，并预计在2026年第二季度启动这项研究。

Coya retains full global rights to this indication, which we believe represents a meaningful long-term value opportunity..

Coya保留了该适应症的全球全部权利，我们认为这代表了一个有意义的长期价值机会。

COYA 303 in Alzheimer’s Disease

阿尔茨海默病中的COYA 303

COYA 303, our proprietary combination of low-dose IL-2 and a GLP-1 receptor agonist, has demonstrated compelling preclinical synergy across multiple biomarkers relevant to neurodegenerative disease. While recent Novo Nordisk EVOKE and EVOKE+ studies evaluating semaglutide monotherapy in mild Alzheimer’s disease did not show clinical efficacy, they did demonstrate some improvement in key biomarkers.

COYA 303是我们专有的低剂量IL-2与GLP-1受体激动剂的组合，在与神经退行性疾病相关的多个生物标志物上展现了令人信服的临床前协同作用。尽管诺和诺德最近在轻度阿尔茨海默病中评估司美鲁肽单药治疗的EVOKE和EVOKE+研究未显示出临床疗效，但它们确实表明一些关键生物标志物有所改善。

We believe the synergy demonstrated from our in vitro and in vivo studies of our proprietary combination of low-dose IL-2 and a GLP-1 receptor agonist (COYA 303) may make this combination a viable approach in Alzheimer’s disease..

我们相信，从我们专有的低剂量IL-2和GLP-1受体激动剂（COYA 303）组合的体外和体内研究中展示的协同作用，可能使这种组合成为阿尔茨海默病的一种可行方法。

In 2026, we will continue to pursue capital-efficient strategies to advance this program, including strategic partnerships and non-dilutive funding opportunities.

2026年，我们将继续追求资本高效策略来推进该计划，包括战略合作伙伴关系和非稀释性融资机会。

Strategic Partnerships

战略伙伴关系

Our collaboration with Dr. Reddy’s Laboratories continues to strengthen and provides substantial value beyond non-dilutive milestone payments. Our teams remain closely aligned in advancing the ALSTARS trial and preparing for potential future commercialization activities. We expect this partnership to deepen further in 2026..

我们与Dr. Reddy’s Laboratories的合作持续加强，并且除了非稀释性里程碑付款之外，还提供了巨大的价值。我们的团队在推进ALSTARS试验以及为未来可能的商业化活动做准备方面，仍然保持紧密协作。我们预计这一合作关系将在2026年进一步深化。

We are also evaluating additional strategic opportunities. Japan represents a significant ALS market where we retain full rights, and we plan to advance discussions with potential partners accordingly. More broadly, as immunology and neuroscience increasingly converge, we see multiple opportunities to expand the reach of our platform through combination strategies and novel collaborations..

我们还在评估其他战略机遇。日本是一个重要的ALS市场，我们在该市场拥有全部权利，我们计划相应地与潜在合作伙伴推进讨论。更广泛地说，随着免疫学和神经科学日益融合，我们看到通过组合策略和新的合作方式来扩大我们平台影响力的多个机会。

Looking Ahead

展望未来

In summary, throughout 2026, Coya will be actively advancing two COYA 302 clinical programs: one in ALS and the other in FTD—two diseases with profound unmet medical need and an estimated combined market opportunity of $2–$4 billion. Our confidence is grounded in three pillars:

总之，在 2026 年全年，Coya 将积极推进两项 COYA 302 临床计划：一项针对肌萎缩侧索硬化症 (ALS)，另一项针对额颞叶痴呆 (FTD)——这两种疾病存在巨大的未满足医疗需求，预计综合市场机会将达到 20 至 40 亿美元。我们的信心建立在三大支柱之上：

Highly validated science rooted in Nobel Prize–recognized discoveries in regulatory T-cell biology that established the central role of Tregs in immune homeostasis and the control of pathologic inflammation.

基于诺贝尔奖认可的调节性T细胞生物学发现的高度验证科学，确立了调节性T细胞在免疫稳态和病理炎症控制中的核心作用。

A combination based therapeutic strategy that targets multiple aspects of the immune system increases the probability of technical and regulatory success.

一种基于组合的治疗策略，针对免疫系统的多个方面，增加了技术和监管成功的概率。

Consistent and encouraging clinical and translational data across multiple studies and indications, supplemented by the generation of additional translational biology datasets in 2026 that we anticipate will further elucidate the role of regulatory T cells in modulating neuroinflammation and neurodegeneration and support our mechanistic and clinical rationale..

跨多项研究和适应症的临床和转化数据一致且令人鼓舞，并且预计2026年生成的更多转化生物学数据集将进一步阐明调节性T细胞在调节神经炎症和神经退行性疾病中的作用，并支持我们的机制和临床依据。

With a strong balance sheet and runway extending beyond our next major clinical inflection point, we believe Coya is well positioned to execute on its strategy and deliver meaningful long-term value.

凭借强大的资产负债表和足以延伸至下一个重大临床转折点的资金跑道，我们相信Coya有能力执行其战略并创造有意义的长期价值。

On behalf of the entire Coya team, thank you for your continued support and confidence. Our management team and board of directors are considerable shareholders along with you, aligning our collective interests. We only win if you win. We are deeply grateful to our employees, investigators, clinical partners, and—most importantly—the patients and families who make our work possible.

代表整个Coya团队，感谢您一直以来的支持与信任。我们的管理团队和董事会与您一样是重要的股东，我们的利益紧密相连。只有您成功，我们才能成功。我们深深感激我们的员工、研究人员、临床合作伙伴，以及最重要的是，使我们的工作成为可能的患者及其家属。

We look forward to updating you on our continued progress throughout the year..

我们期待在全年中不断更新您我们的持续进展。

Sincerely yours,

此致，

Arun Swaminathan, Ph.D.

阿伦·斯瓦米纳森，博士

Chief Executive Officer

首席执行官

Coya Therapeutics, Inc.

科亚治疗公司

About Coya Therapeutics, Inc.

关于Coya治疗公司，Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases.

总部位于德克萨斯州休斯顿的Coya Therapeutics, Inc.（纳斯达克代码：COYA）是一家临床阶段的生物技术公司，致力于开发基于调节性T细胞（“Tregs”）生物学特性及其潜在治疗优势的专有疗法，以针对系统性炎症和神经炎症。Tregs功能异常是多种疾病的根源，包括神经退行性疾病、代谢性疾病和自身免疫性疾病。

This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system..

这种细胞功能障碍可能导致持续的炎症和氧化应激，从而导致免疫系统稳态的缺失。

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Coya的研发产品候选管线利用多种治疗模式，旨在恢复Treg的抗炎和免疫调节功能。Coya的治疗平台包括增强Treg的生物制剂、Treg衍生的外泌体以及自体Treg细胞疗法。

For more information about Coya, please visit

有关 Coya 的更多信息，请访问

www.coyatherapeutics.com

About COYA 302

关于COYA 302

COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 comprises proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS and other neurodegenerative diseases.

COYA 302 是一种研究性、专有的生物组合疗法，具有双重免疫调节作用机制，旨在增强调节性 T 细胞 (Tregs) 的抗炎功能，并抑制活化的单核细胞和巨噬细胞产生的炎症。COYA 302 包含专有的低剂量白介素-2 (LD IL-2) 和 CTLA-4 Ig，正在开发用于皮下注射治疗 ALS 和其他神经退行性疾病患者。

These mechanisms may have additive or synergistic effects..

这些机制可能具有相加或协同效应。

Coya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (

Coya目前正在开展ALSTARS试验，这是一项二期、随机、多中心、双盲、安慰剂对照的研究，旨在评估COYA 302治疗ALS的疗效和安全性（

ClinicalTrials.gov

临床试验.gov

Identifier: NCT 07161999).

标识符：NCT 07161999）。

COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.

COYA 302 是一种研究性产品，尚未获得 FDA 或任何其他监管机构的批准。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, our anticipated cash runway, industry environment and potential market opportunities.

本新闻稿包含基于管理层信念、假设以及管理层目前可获得信息的“前瞻性”陈述。前瞻性陈述包括本报告中除历史事实陈述之外的所有陈述，包括有关我们当前和未来的财务表现、业务计划与目标、当前和未来的临床及临床前开发活动、正在进行和计划中的临床试验及其相关数据的时间安排与成功性、我们临床试验及相关数据的公告、更新和结果的时间、我们获得并维持监管批准的能力、我们候选产品的潜在治疗效益与经济价值、竞争地位、预期的现金跑道、行业环境和潜在市场机会的信息。

The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements..

“相信”、“可能”、“将”、“估计”、“继续”、“预期”、“打算”、“期望”等词语及类似表达旨在识别前瞻性陈述。

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress and timing of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; our exploratory clinical signals may not be predictive of outcomes in larger, randomized controlled trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; anticipated interactions with the FDA under Fast Track designation; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional p.

前瞻性声明受到已知和未知风险、不确定性、假设及其他因素的影响，包括但不限于与我们的候选产品开发活动及正在进行和计划中的临床试验的成功、成本和时间相关的风险；我们开发和商业化靶向治疗的计划；我们在临床前或临床试验中患者入组和给药的进展和时间；我们的候选产品在临床试验中达到适用终点的能力；我们的探索性临床信号可能无法预测更大规模随机对照试验的结果；我们的候选产品的安全性特征；我们的临床试验数据可能支持上市申请的潜力以及这些事件的时间；我们为运营获得资金的能力；我们的候选产品的开发和商业化；我们获得并维持监管批准的时间和能力；在快速通道指定下与FDA预期的互动；我们的候选产品市场接受度和临床应用的速率和程度；我们的候选产品市场的规模和增长潜力，以及我们服务这些市场的能力；我们的商业化、营销和制造能力及策略；与第三方就我们候选产品的商业化达成的未来协议；我们对我们获得并维持知识产权保护能力的预期；我们对第三方制造商的依赖；竞争性疗法或产品的成功或可用性；我们吸引和留住关键科学或管理人员的能力；我们识别额外的能力。

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs.

我们做出这些前瞻性陈述的主要依据是当前的预期和对未来事件及趋势的预测，我们认为这些事件和趋势可能会影响我们的财务状况、经营成果、业务战略、短期和长期业务运营及目标，以及财务需求。

Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

此外，我们处在一个竞争非常激烈且变化迅速的环境中，新的风险可能会不时出现。我们的管理层无法预测所有风险，也无法评估所有因素对我们业务的影响，或任何因素或因素组合导致实际结果与我们可能做出的前瞻性陈述中包含的结果产生重大差异的程度。

In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur.

鉴于这些风险、不确定性和假设，本文讨论的前瞻性事件和情况可能不会发生，实际结果可能与前瞻性声明中预期或暗示的结果存在重大差异，并产生不利影响。尽管我们的管理层认为前瞻性声明中反映的预期是合理的，但我们无法保证前瞻性声明中描述的未来结果、活动水平、绩效或事件和情况将会实现或发生。

We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise..

我们不承担公开更新任何前瞻性声明的义务，无论这些声明是书面还是口头作出的，也无论其是否因新信息、未来发展或其他原因而做出。

Investor Contact

投资者联系方式

David Snyder, CFO

大卫·斯奈德，首席财务官

david@coyatherapeutics.com

大卫@科亚治疗学.com

astr partners

天体伙伴

Matthew Beck

马修·贝克

matthew.beck@astrpartners.com